Shire
SHP: 4,332.30 -115.25 (▼2.60%)
| Bid Price | 4,315.00 | High Price | 4,417.50 |
|---|---|---|---|
| Ask Price | 4,319.50 | Low Price | 4,308.50 |
| Open Price | 4,398.50 | Spread | 0.10% |
| Prev Close | 4,315.00 | Volume | 2,410,638.00 |
Shire Share Price Chart
Intraday
Historic – 1 year
Shire Share Price Information
| Name | Shire | Epic | SHP |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | JE00B2QKY057 |
| Activites | Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetics. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US. | Security Type | Equity |
Key numbers
| Latest Share Price (p) | 4,317.25 | Net Gearing (%) | 40.01 |
|---|---|---|---|
| Market Cap (£m) | 39,148.23 | Gross Gearing (%) | 40.82 |
| Shares in issue (m) | 904.01 | Debt Ratio | 23.83 |
| P/E Ratio | 19.62 | Debt-to-Equity Ratio | 0.45 |
| Divs per share (p) | 18.01 | Assets / Equity Ratio | 1.69 |
| Dividend Yield (%) | 0.28 | Price to book value | 3.98 |
| Dividend Cover | 12.06 | SROCE (%) | 10.74 |
| Earning per share (p) | 220.70 | EPS Growth (%) | -61.98 |
| 52-week high / low (p) | 5,509.50 / 3,423.00 | DPS Growth (%) | 22.10 |
Shire Broker Views
| Date | Broker | Rec. | Price | Old target price | New target price | Notes |
|---|---|---|---|---|---|---|
| 06 Dec | JP Morgan Cazenove | Overweight | 4,332.30 | 6300.00 | 6300.00 | Reiterates |
| 05 Dec | Bryan Garnier | Buy | 4,332.30 | 6800.00 | Reiterates | |
| 05 Dec | Deutsche Bank | Buy | 4,332.30 | Reiterates | ||
| 05 Dec | JP Morgan Cazenove | Overweight | 4,332.30 | Reiterates | ||
| 28 Nov | JP Morgan Cazenove | Overweight | 4,332.30 | Reiterates |
Shire Director Deals
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 30 Jun 2016 | Anne Minto | Buy | 179 @ 4463.06p | £7,988.88 |
| 30 Jun 2016 | Bill Burns | Buy | 190 @ 4463.06p | £8,479.81 |
| 30 Jun 2016 | Olivier Bohoun | Buy | 134 @ 4463.06p | £5,980.50 |
| 30 Jun 2016 | Dominic Blakemore | Buy | 150 @ 4463.06p | £6,694.59 |
Shire Company News
Broker Forecast – Bryan Garnier issues a broker note on Shire PLC
Bryan Garnier today reaffirms its buy investment rating on Shire PLC (LON:SHP) and set its price target at 6800p.
Story provided by StockMarketWire.com
BP and Shire results hit FTSE
The blue chip index was dragged into the red as BP (BP.) reported a decline in underlying profit and Shire (SHP) revealed a slump in its haemophilia product sales.
Royal Dutch Shell (RDSB) was unable to lift the FTSE higher despite posting its first quarter sales increase in three years. The stock gained 4%.
The UK’s manufacturing sector maintained a solid rate of expansion despite Markit’s purchasing managers’ index dipping from 55.5 in September to 54.3 in October. Upturns in output, new orders and employment were noted.
West Texas Intermediate (WTI) crude oil fell 0.9% to $46.43 and Brent crude oil was 0.9% lower at $48.18 per barrel, respectively.
Gold jumped by more than 1% as markets started to fear a Trump victory in the forthcoming US elections. Copper rallied nearly 1% to $4,894 per tonne.
FTSE 100 RISERS AND FALLERS
Shire (SHP) needed a shot in the arm following a slump in haemophilia product sales and higher integration costs than expected for US-based Baxalta. The shares traded 2.6% lower at £45.27.
Shares in rival oil company BP (BP.) slid 4.5% on a year-on-year decline in third quarter profit. This was caused by ‘a weaker price and margin environment’ as well as higher exploration write-offs and rig cancellation charges in the upstream business.
Standard Chartered (STAN) CEO Bill Winters said income and profit levels were ‘not yet acceptable’, pushing its share price 5.4% lower to 673.3p.
FTSE 250 RISERS AND FALLERS
Price comparison site Moneysupermarket (MONY) was marked up 10% to 287.9p after reporting a strong third quarter performance, with sales up 12%, as it remained on track for a record year.
Specialist engineer Weir (WEIR) traded 2.3% lower on a full year profit warning. A muted third quarter performance reflected a low point in the North American oil and gas market and tougher conditions in the Middle East.
Bus and rail group Go-Ahead (GOG) was flat despite passenger revenue being hit by strikes on the Southern network, which is part of its 65%-owned Govia Thameslink Railway. The transport group said it was on track to meet full year forecasts.
Virgin Money (VM.) said it expected no material impact from Brexit, but noted the UK economy’s outlook was unclear. Shares dipped 2.7% as investors were concerned.
SMALL CAP RISERS AND FALLERS
Northern Petroleum (NOP) was one of the biggest small cap risers as the stock traded 16.2% higher on total proven plus probable reserves of 1.9 million barrels of oil equivalent at its development and production assets in Canada.
Shares in museum exhibit design firm Paragon Entertainment (PEL) soared 29% after it said trading was ahead of expectations thanks to a tighter focus on its ‘design and build’ business.
Franchise Brands (FRAN) jumped 12.4% to 59p after making its first acquisition since floating in August. It bought dog sitting franchise Barking Mad.
Maintenance firm Bilby (BILB) issued a profit warning, blaming a ‘change in processes’ from a major public sector customer. This caused delays in expected work and triggered a 10.4% drop in the share price to 71.7p.
Gambling group Sportech (SPO) fell into negative territory as discussions to sell The Football Pools for £97.25m were terminated.
Investors toasted drinks distributor Conviviality (CVR) after a strong first half performance. Sales were up 211% at £783m in the half year to October, reflecting organic growth and a boost from a trio of acquisitions spearheaded by drinks wholesaler Matthew Clark.
Story provided by StockMarketWire.com
Broker Forecast – Bryan Garnier issues a broker note on Shire PLC
Bryan Garnier today reaffirms its buy investment rating on Shire PLC (LON:SHP) and set its price target at 6900p.
Story provided by StockMarketWire.com
Broker Forecast – HSBC issues a broker note on Shire PLC
HSBC today reaffirms its hold investment rating on Shire PLC (LON:SHP) and cut its price target to 5200p (from 5250p).
Story provided by StockMarketWire.com
FTSE struggles on lack of blue-chip news
The FTSE 100 failed to gain positive momentum on a quiet corporate day amid struggling housebuilding stocks.
The blue-chip index closed 1.3% lower at 6,818.
Housebuilders Taylor Wimpey (TW.) and Barratt (BDEV) slumped by up to 4.1%, while UK supermarkets weakened on news that German discounter Aldi achieved record sales and announced a £300 million investment in its stores.
Tesco (TSCO), Sainsbury’s (SBRY) and Morrisons (MRW) were pushed into the red.
West Texas Intermediate (WTI) crude oil advanced 3.5% to $46 and Brent crude oil gained 3.3% to $47.42 per barrel, respectively.
Gold glittered at $1,340 per ounce and copper fell 0.3% to $4,806 per tonne.
BLUE CHIP RISERS AND FALLERS
WPP (WPP) fell 2.5% lower after broker Jeffries International downgraded its rating from hold to buy and cut its price target.
Pharmaceutical firm Shire (SHP) retreated 1.7% following HSBC’s downgrade from hold to buy and cut in price target.
MID CAP RISERS AND FALLERS
Scandal-hit Sports Direct (SPD) declined 6% despite an initial positive reaction to Mike Ashley taking over as CEO following Dave Forsey’s resignation on Friday.
Broker Peel Hunt’s downgrade from add to hold for events company UBM (UBM) accompanied a 2.8% slump in the share price.
SMALL CAP RISERS AND FALLERS
Creative media agency MediaZest (MDZ) was hot off the presses after announcing £250,000 of new business wins since 12 August. Its share price climbed 18.2% to 0.16p.
The market dug Thor Mining (THR) on its confident outlook concerning securing enough money for the Molyhil tungsten project, triggering a share price rise of 20%.
Drug development company Summit Therapeutics (SUMM) received fast track designation from the US Food and Drug Administration for ezutromid in the treatment of Duchenne muscular dystrophy.
Malaysian data centre operator CSF (CSFG) plummeted 51.1% to 0.43p on news it intends to seek shareholder approval to delist from the AIM market.
Oil rig refurbishment specialist Lamprell (LAM) was one of the biggest risers on the London Stock Exchange, rising 11.9% to 71.63p after winning a $90 million contract from new client Master Marine. Lamprell will upgrade its mobile operating unit as an accommodation service vessel for Statoil’s Johan Sverdrup field offshore Norway.
Investors were impressed by housebuilder MJ Gleeson’s (GLE) 20.5% growth in annual pre-tax profit to £28.2 million and hiked dividend of 45% to 14.5p. The company said trading was ‘business as usual’ since the EU referendum.
North River Resources (NRRP) fell 18.5% after reporting mixed results at its Namib project, which requires a critical period of assessment to determine how to proceed.
Green gas company Good Energy (GOOD) rose 9.1% to 261.5p following a positive article in The Mail On Sunday.
Brand experience specialist SpaceandPeople (SAL) crashed 34.2% to 26p after swinging from a profit of £62,000 to a £174,000 loss in the first half of the year due to ‘subdued trading’. The firm also suspended dividends temporarily.
Respiratory disease-focused drug developer Verona Pharma (VRP) got a shot in the arm following upbeat management expectations for smokers cough treatment RPL554. It also revealed Piers Morgan as chief financial officer, who used to be chief executive of C4X Discovery (C4XD).
Story provided by StockMarketWire.com
